Authors
ED Michelakis, G Sutendra, P Dromparis, L Webster, A Haromy, E Niven, C Maguire, T-L Gammer, JR Mackey, D Fulton, B Abdulkarim, MS McMurtry, KC Petruk
Publication date
2010/5/12
Journal
Science translational medicine
Volume
2
Issue
31
Pages
31ra34-31ra34
Publisher
American Association for the Advancement of Science
Description
Solid tumors, including the aggressive primary brain cancer glioblastoma multiforme, develop resistance to cell death, in part as a result of a switch from mitochondrial oxidative phosphorylation to cytoplasmic glycolysis. This metabolic remodeling is accompanied by mitochondrial hyperpolarization. We tested whether the small-molecule and orphan drug dichloroacetate (DCA) can reverse this cancer-specific metabolic and mitochondrial remodeling in glioblastoma. Freshly isolated glioblastomas from 49 patients showed mitochondrial hyperpolarization, which was rapidly reversed by DCA. In a separate experiment with five patients who had glioblastoma, we prospectively secured baseline and serial tumor tissue, developed patient-specific cell lines of glioblastoma and putative glioblastoma stem cells (CD133+, nestin+ cells), and treated each patient with oral DCA for up to 15 months. DCA depolarized …
Total citations
20102011201220132014201520162017201820192020202120222023202485869729794726753574950413225
Scholar articles
ED Michelakis, G Sutendra, P Dromparis, L Webster… - Science translational medicine, 2010